Merck & Co., Inc. (NYSE:MRK) Shares Sold by Hennessy Advisors Inc.

Samuel Edwards

Published on:

Hennessy Advisors Inc. trimmed its holdings in Merck & Co., Inc. (NYSE:MRK) by 2.0% throughout the third quarter, in line with its most up-to-date submitting with the Securities and Change Fee (SEC). The agency owned 88,000 shares of the corporate’s inventory after promoting 1,800 shares throughout the quarter. Hennessy Advisors Inc.’s holdings in Merck & Co., Inc. had been value $7,300,000 on the finish of the latest quarter.

A number of different institutional buyers have additionally made adjustments to their positions within the firm. Ropes Wealth Advisors LLC elevated its holdings in shares of Merck & Co., Inc. by 0.5% within the third quarter. Ropes Wealth Advisors LLC now owns 43,901 shares of the corporate’s inventory valued at $3,642,000 after buying an extra 230 shares throughout the interval. Cardinal Capital Administration grew its place in Merck & Co., Inc. by 0.7% within the third quarter. Cardinal Capital Administration now owns 61,287 shares of the corporate’s inventory valued at $5,084,000 after shopping for an extra 432 shares over the last quarter. IBM Retirement Fund grew its place in Merck & Co., Inc. by 36.6% within the third quarter. IBM Retirement Fund now owns 86,239 shares of the corporate’s inventory valued at $7,154,000 after shopping for an extra 23,097 shares over the last quarter. QCI Asset Administration Inc. NY grew its place in Merck & Co., Inc. by 12.0% within the third quarter. QCI Asset Administration Inc. NY now owns 6,330 shares of the corporate’s inventory valued at $525,000 after shopping for an extra 679 shares over the last quarter. Lastly, VeraBank N.A. grew its place in Merck & Co., Inc. by 2.2% within the third quarter. VeraBank N.A. now owns 10,839 shares of the corporate’s inventory valued at $899,000 after shopping for an extra 231 shares over the last quarter. 73.18% of the inventory is presently owned by institutional buyers and hedge funds.

In associated information, CFO Robert M. Davis offered 251,273 shares of the enterprise’s inventory in a transaction dated Monday, October fifth. The shares had been offered at a median value of $81.03, for a complete worth of $20,360,651.19. Following the sale, the chief monetary officer now instantly owns 422,329 shares within the firm, valued at roughly $34,221,318.87. The transaction was disclosed in a authorized submitting with the Securities & Change Fee, which is on the market by means of this hyperlink. Additionally, EVP Frank Clyburn offered 18,876 shares of the enterprise’s inventory in a transaction dated Wednesday, August fifth. The shares had been offered at a median value of $81.55, for a complete transaction of $1,539,337.80. Following the completion of the transaction, the manager vp now instantly owns 99,639 shares of the corporate’s inventory, valued at roughly $8,125,560.45. The disclosure for this sale will be discovered right here. Insiders offered a complete of 280,529 shares of firm inventory value $22,761,633 during the last quarter. Insiders personal 0.28% of the corporate’s inventory.

A variety of analysis corporations just lately weighed in on MRK. JPMorgan Chase & Co. lifted their value goal on shares of Merck & Co., Inc. from $98.00 to $105.00 and gave the corporate an “obese” score in a analysis report on Friday. Mizuho reiterated a “purchase” score on shares of Merck & Co., Inc. in a analysis report on Tuesday, September twenty second. SVB Leerink lifted their value goal on shares of Merck & Co., Inc. from $95.00 to $100.00 and gave the corporate an “outperform” score in a analysis report on Tuesday, August twenty fifth. Royal Financial institution of Canada reiterated a “maintain” score on shares of Merck & Co., Inc. in a analysis report on Tuesday, August 4th. Lastly, ValuEngine lowered shares of Merck & Co., Inc. from a “maintain” score to a “promote” score in a analysis report on Thursday, October 1st. One equities analysis analyst has rated the inventory with a promote score, two have issued a maintain score and eleven have given a purchase score to the corporate’s inventory. The inventory presently has a median score of “Purchase” and a median value goal of $95.08.

Merck & Co., Inc. inventory opened at $78.67 on Tuesday. Merck & Co., Inc. has a 52 week low of $65.25 and a 52 week excessive of $92.64. The corporate has a fast ratio of 1.05, a present ratio of 1.32 and a debt-to-equity ratio of 0.94. The agency’s 50-day easy transferring common is $82.92 and its 200 day easy transferring common is $80.49. The agency has a market capitalization of $198.98 billion, a PE ratio of 19.19, a P/E/G ratio of two.10 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK) final launched its quarterly earnings knowledge on Friday, July thirty first. The corporate reported $1.37 EPS for the quarter, topping the consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a web margin of twenty-two.20% and a return on fairness of 52.94%. The enterprise had income of $10.87 billion for the quarter, in comparison with analyst estimates of $10.52 billion. Throughout the identical interval within the earlier yr, the agency earned $1.30 EPS. The enterprise’s income for the quarter was down 7.6% in comparison with the identical quarter final yr. On common, analysis analysts count on that Merck & Co., Inc. will submit 5.68 EPS for the present fiscal yr.

The agency additionally just lately disclosed a quarterly dividend, which was paid on Wednesday, October seventh. Traders of file on Tuesday, September fifteenth got a $0.61 dividend. The ex-dividend date was Monday, September 14th. This represents a $2.44 annualized dividend and a dividend yield of three.10%. Merck & Co., Inc.’s dividend payout ratio is presently 47.01%.

About Merck & Co., Inc.

Merck & Co, Inc supplies healthcare options worldwide. It operates by means of 4 segments: Pharmaceutical, Animal Well being, Healthcare Companies, and Alliances. The corporate affords therapeutic and preventive brokers to deal with cardiovascular, kind 2 diabetes, persistent hepatitis C virus, HIV-1 an infection, intra-abdominal, fungal an infection, insomnia, and inflammatory illnesses.

Really helpful Story: What’s a administration payment?

Wish to see what different hedge funds are holding MRK? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Obtain Information & Scores for Merck & Co. Inc. Every day – Enter your electronic mail tackle beneath to obtain a concise day by day abstract of the newest information and analysts’ scores for Merck & Co. Inc. and associated corporations with MarketBeat.com’s FREE day by day electronic mail publication.

Leave a Comment